Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
Silence Therapeutics to Present at Jefferies London Healthcare Conference